The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998 • 2,777 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

1994 • 1,932 citations

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

1997 • 1,652 citations

Monoclonal antibody therapy of cancer

2005 • 1,209 citations

FcR γ chain deletion results in pleiotrophic effector cell defects

1994 • 967 citations

Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

1998 • 914 citations

B Cell Development in the Spleen Takes Place in Discrete Steps and Is Determined by the Quality of B Cell Receptor–Derived Signals

1999 • 843 citations

Chronic Lymphocytic Leukemia

1995 • 799 citations

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

2003 • 753 citations

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1994 • 747 citations

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

1999 • 653 citations

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

1997 • 638 citations

The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

2004 • 632 citations

Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

2001 • 603 citations

CD20: a regulator of cell-cycle progression of B lymphocytes

1994 • 583 citations

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

1998 • 576 citations

Positive Selection of Natural Autoreactive B Cells

1999 • 574 citations

Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo

2003 • 557 citations

Radioimmunotherapy of B-Cell Lymphoma with [¹³¹I]Anti-B1 (Anti-CD20) Antibody

1993 • 557 citations

Abnormal B lymphocyte delevopment, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule

1995 • 546 citations

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

2001 • 523 citations

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

2001 • 521 citations

Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.

1995 • 496 citations

L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites.

1995 • 450 citations

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

2001 • 425 citations

The half-lives of serum immunoglobulins in adult mice

1988 • 425 citations

Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

1997 • 411 citations

B1 cells: similarities and differences with other B cell subsets

2001 • 387 citations

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

2003 • 384 citations

Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy

2003 • 363 citations

Complement activation plays a key role in the side‐effects of rituximab treatment

2001 • 324 citations

CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity.

1996 • 263 citations

Mouse CD20 expression and function

2003 • 238 citations

Analysis of Th1 and Th2 cells in murine gut-associated tissues. Frequencies of CD4+ and CD8+ T cells that secrete IFN-gamma and IL-5.

1990 • 226 citations

Pathogenic Roles of B Cells in Human Autoimmunity

2004 • 222 citations

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

2001 • 220 citations

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

2003 • 213 citations

Feedback regulation of murine Ly‐1 B cell development

1989 • 161 citations

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

1997 • 154 citations

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

2002 • 133 citations

Rituximab

1999 • 131 citations

Rituximab for Treatment of Advanced Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Lymphoma

2003 • 122 citations

Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys

2003 • 118 citations

Influence of antibody isotype on passive serotherapy of lymphoma.

1985 • 112 citations

Immunotherapy of Non-Hodgkin's Lymphomas

2001 • 105 citations

Clinical status and optimal use of rituximab for B-cell lymphomas.

1998 • 84 citations

Effects of specific anti‐B and/or anti‐plasma cell immunotherapy on antibody production in baboons: depletion of CD20‐ and CD22‐positive B cells does not result in significantly decreased production of anti‐αGal antibody

2001 • 61 citations

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1994 • 60 citations

Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys

2003 • 37 citations

Anti-CD20 Monoclonal Antibody Treatment of Human Herpesvirus 8-Associated, Body Cavity-Based Lymphoma with an Unusual Phenotype in a Human Immunodeficiency Virus-Negative Patient

2001 • 36 citations

B cell–ablative therapy for the treatment of autoimmune diseases

2002 • 32 citations

Kinetics of peritoneal B‐1a cells (CD5 B cells) in young adult mice

1993 • 31 citations

Androgen-independent prostate cancer: not so chemorefractory after all.

1999 • 12 citations